Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.

Inclusion Criteria:

• Scheduled to receive nonmyeloablative conditioning which includes fludarabine
• Scheduled to receive a haploidentical graft
• Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid
• Age >18 years at the time of enrollment

Exclusion Criteria:

• Diagnosed with an immunodeficiency disorder, including HIV